University of California

Origen Therapeutics, Inc.

Kham M Trinh

Sherie L Morrison

John M Timmerman

Robert Etches

Mansoor S Mohammed

Alex Vasuthasawat

Koteswara R Chintalacharuvu

M Josefina Coloma

Esther Mikyung Yoo

Letitia A Wims

Reiko King

Alan G Wildeman

Patricia Young

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a nutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

Anti-CSPG4 fusions with interferon for the treatment of malignancy

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a mutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

Methods for preparing recombinant proteins, such as antibodies, in eggs are described. The method offers advantages over existing systems for preparing recombinant proteins including high yield, low cost and compatibility with animal protection regulations. In addition, since eggs are edible food sources the recombinant protein does not have to be isolated from the egg.

Production of proteins in eggs

Disclosed are modified immunoglobulin (Ig) molecules, a method of producing modified Ig molecules, and methods for treatment and prevention of infectious diseases using modified Ig molecules. In one embodiment, the modified Ig molecule comprises a C,3 domain of an IgA molecule (&agr; C,3). The combination of an &agr; C,3 with other domains selected from one or more nonIgA Ig molecules provides an Ig molecule that has the capacity to bind J chain and/or secretory component (SC) together with features of a nonIgA molecule. In another embodiment, the modified Ig molecule comprises a C,1 and/or a C,2 domain of an IgA molecule. The combination of an &agr; C,1 and/or C,2 domain with other domains selected from one or more nonIgA Ig molecules provides an Ig molecule that has the capacity to form higher polymers (trimers, tetramers, pentamers, etc.) together with features of a nonIgA molecule. In one embodiment, the modified immunoglobulin molecule lacks one or more carbohydrate addition sites.

Growing community of inventors

Alhambra, CA, United States of America

Kham M Trinh